08-01-05

Docket No: AM100986 Patent

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of:

Ronald Charles Bernotas et al.

Application No.:

10/621,698

Group Art No.:

1625

Filed:

July 17, 2003

Examiner:

1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE

Chang, Celia C

DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS

onfirmation No.:

1509

ustomer Number:

25291

Mail Stop Amendment Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

### AMENDMENT TRANSMITTAL LETTER

- 1. Enclosed please find the following documents for the above-identified application:
  - a) Response to Office Action mailed on May 6, 2005; and
  - b) Terminal Disclaimer.

## **CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV100496429US addressed to the Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Docket No: AM100986

Patent

### 2. Fee calculation

CLAIMS AS AMENDED							
(1)	(2)	(3)	(4)				(5)
FOR TOTAL CLAIMS INDEPENDENT	CLAIMS REMAINING AFTER AMENDMENT 14 3	HIGHEST NUMBER PAID FOR 20 4	NUMBER EXTRA x  RATE  0 x \$ 18.00  0 x \$ 86.00			ADDITIONAL FEE 0.00 0.00	
CLAIMS MULTIPLE DEPENDENCY FEE					\$	290.00	
Total Amendment Fee						ent Fee:	\$0.00

Please charge Deposit Account No. 01-1425 for: \$0.00

The Commissioner is hereby authorized to charge any additional fees required by this paper, including the enclosed documents, and during the entire pendency of this application and to credit any excess amounts paid to Deposit Account No. 01-1425. A copy of this letter is enclosed for use by the Deposit Account Branch.

Respectfully submitted,

Barbara L. Lences Agent for Applicants

Reg. No. 41,148

Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (732) 274-4678

Docket No: AM100986

Patent

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

ation of:

Ronald Charles Bernotas et al.

Application No.:

10/621,698

Group No.: 1625

Filed:

July 17, 2003

Examiner:

For:

Chang, Celia C 1-HETEROCYCLYLALKYL-3-SULFONYLINDOLE OR -INDAZOLE

**DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS** 

Confirmation No.:

1509

Customer Number:

25291

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

## AMENDMENT

In response to the office action dated May 6, 2005, please consider the following remarks.

## **REMARKS**

The present invention provides 1-heterocyclylalkyl-3-sulfonylindole derivatives of formula I and the therapeutic use thereof for the treatment of central nervous system disorders related to or affected by the 5-hydroxytryptamine-6 receptor.

Claims 1-8 and 15-20 are pending.

Claims 1-8 and 15-20 have been rejected under the judicially created doctrine of obviousness type double patenting over claims 1-9 and 15-19 of US 6,272,246.

While not implying any agreement with Examiner's rejection, Applicants submit herewith a Terminal Disclaimer over US 6,272,246. Applicants believe the enclosed Terminal Disclaimer overcomes the double patenting rejection.

#### **CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV100496429US addressed to the Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.